CVA Family Office LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

CVA Family Office LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.2% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 140 shares of the biopharmaceutical company’s stock after selling 25 shares during the period. CVA Family Office LLC’s holdings in Regeneron Pharmaceuticals were worth $74,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Activest Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $27,000. Colonial Trust Advisors bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Finally, SouthState Corp raised its position in Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 44 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.4%

Shares of Regeneron Pharmaceuticals stock opened at $577.95 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $943.83. The firm has a market cap of $61.26 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31. The company has a 50-day moving average of $576.32 and a 200 day moving average of $562.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter in the prior year, the company earned $11.56 earnings per share. The business’s revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Saturday. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $802.35.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.